Results 81 to 90 of about 5,643 (237)

CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. [PDF]

, 2020
BackgroundLong non-coding RNAs (lncRNAs) exhibit highly cell type-specific expression and function, making this class of transcript attractive for targeted cancer therapy.
Akeson, Mark, Birk, Harjus S, Gupta, Nalin, He, Daniel, Hong, Sung Jun, Horlbeck, Max A, Jain, Miten, Koontz, Mark, Lien, Brian V, Lim, Daniel A, Liu, S John, Malatesta, Martina, Monje, Michelle, Olsen, Hugh E, Pedraza, Leslie, Raleigh, David R, Saha, Parna, Seo, Kyounghee, Thombare, Shivani S, Ullian, Erik M, Weissman, Jonathan S   +20 more
core   +1 more source

Canonical and Non‐Canonical Functions of Histone H3K4 Methylation Modifiers in Cancer

Cancer Science, Volume 116, Issue 11, Page 2940-2948, November 2025.
Histone H3K4‐modifying enzymes regulate gene expression and cellular processes critical to cancer development. Beyond their canonical roles, these enzymes also exhibit non‐catalytic and non‐histone functions, offering new opportunities for therapeutic intervention. ABSTRACT Histone H3K4 modifications are altered in the regulation of gene expression and
Takayuki Hoshii
wiley   +1 more source

A curious case of T2-FLAIR mismatch in H3K27M mutant glioma

Radiology Case Reports, 2022
Diffuse midline gliomas are a rare relatively new classification of primary central nervous system tumors which include astrocytomas, oligodendrogliomas, and glioblastomas. The T2-FLAIR mismatch sign is regarded as a highly specific imaging feature of IDH-mutant, 1p/19q non-codeleted astrocytomas.
William L. Valentino, Darren Okada, Shiv Bhanu   +2 more
openaire   +3 more sources

Cancer Neuroscience: Decoding Neural Circuitry in Tumor Evolution for Targeted Therapy

Advanced Science, Volume 12, Issue 38, October 13, 2025.
This review highlights the pivotal role of the nervous system in cancer progression, emphasizing how neural–tumor interactions—via synaptic signaling, neurotransmitters, and paracrine factors—reshape the tumor microenvironment. It introduces cancer neuroscience as an emerging field and proposes integrating advanced tools such as AI and optogenetics to ...
Mengyu Yuan, Rongjiao Xi, Yong Kang, Ming‐jie Kuang, Xiaoyuan Ji   +4 more
wiley   +1 more source

IS METHYLATION STATUS SUBGROUPING REALLY A STRONG PROGNOSTIC FACTOR IN PEDIATRIC POSTERIOR FOSSA EPENDYMOMA?

Hematology, Transfusion and Cell Therapy, 2021
Objective: The effective treatment of posterior fossa ependymomas is surgery followed by radio-chemotherapy. Our aim is to evaluate the effects of sex, age, methylation subgrouping, extent of resection, radiation treatment (RT), MIB-1 index, grade, ATRX ...
Bahattin Tanrıkulu, Ayça Erşen Danyeli, Cengiz Canpolat, M. Memet Özek   +3 more
doaj   +1 more source

Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

Cancer Innovation, Volume 4, Issue 5, October 2025.
This article, centered on precision therapy, argues that traditional disease‐centered clinical trials are flawed with prolonged cycles, insufficient early‐phase samples, and inflexible protocols, thus proposing the concept of “clinical trial re‐innovation.” It elaborates that this re‐innovation, driven by biomarker technology, multi‐arm multi‐stage ...
Shenglan Li, Jiachen Wang, Zhuang Kang, Xun Kang, Feng Chen, Wenbin Li   +5 more
wiley   +1 more source

Clinicopathology & Molecular Analysis of Diffuse Intrinsic Pontine Glioma (DIPG) in Children - Insights from Past, Present, and Future Directions [PDF]

, 2022
Diffuse Intrinsic Pontine Glioma, or DIPG, is a rare, highly aggressive, heterogeneous group of brainstem tumors. Around 10-20% of primary brain tumors are considered pediatric brain tumors, of which 10-15% are diffuse brainstem tumors.
Biswas, Arupam
core   +2 more sources

Use of DNA Methylation Profiling as a Molecular Classification Tool for Paediatric Central Nervous System Tumours: A Middle‐Income Country Population–Based Study

Neuropathology and Applied Neurobiology, Volume 51, Issue 5, October 2025.
ABSTRACT Paediatric central nervous system (CNS) tumours are the second most common childhood malignancy and the leading cause of cancer‐related mortality in this age group. Histopathological diagnosis can be challenging, particularly for rare or ambiguous tumours, and may result in misclassification.
Mayara F. Euzébio, Felipe L. T. Silva, Iva L. Hoffmann, Juliana S. Ruas, Larissa Akemi Kido, Dieila G. de Lima, Luciano Queiroz, Izilda A. Cardinalli, Ana Luiza Seidinger, Suelen Nascimento, Helder Tedeschi, Renato D. Puga, Priscila Pini Zenatti Sales, Patricia Y. Jotta, Mariana Maschietto   +14 more
wiley   +1 more source

Oncohistones:Drivers of pediatric cancers [PDF]

, 2017
One of the most striking results in the area of chromatin and cancer in recent years has been the identification of recurrent mutations in histone genes in pediatric cancers.
Helin, Kristian, Mohammad, Faizaan
core   +1 more source

Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes

Molecular Oncology, Volume 19, Issue 9, Page 2648-2669, September 2025.
Raphin‐1 reduces the survival of PED‐DHGG cells and enhances their radiation sensitivity through both PeIF2α‐dependent and PeIF2α‐independent mechanisms. Raphin‐1 sustains elevated levels of PeIF2α, contributing to its PeIF2α‐dependent effects. Additionally, raphin‐1 interacts with CReP to mediate a separate radiosensitizing pathway that operates ...
Karin Eytan, Moshe Leitner, Amos Toren, Shoshana Paglin, Michal Yalon   +4 more
wiley   +1 more source